全病毒颗粒疫苗与裂解病毒颗粒疫苗经溶解微针接种对小鼠H1N1和H5N1流感病毒攻击的保护效力
本研究开发了一种新型溶解微针贴片用于流感疫苗,并分别制备了基于A/Puerto Rico/8/1934(H1N1)和A/duck/Hokkaido/Vac-3/2007(H5N1)的裂解病毒颗粒疫苗与全病毒颗粒疫苗,在小鼠中比较了微针接种与皮下接种的效力。微针接种诱导的中和抗体应答高于皮下接种,且微针接种较低剂量抗原即可提供针对流感病毒致死攻击的保护性免疫。结果提示,全病毒颗粒疫苗经微针接种是流感疫苗的有效组合,需进一步在人体中验证。
要点
- 微针接种诱导的中和抗体应答高于皮下接种。
- 微针接种较低剂量抗原即可提供针对致死攻击的保护。
- 全病毒颗粒疫苗与微针接种的组合需进一步在人体中验证。
核心结论
- 全病毒颗粒疫苗经微针接种是流感疫苗的有效组合,需进一步在人体中验证。
研究设计与样本
- 研究开发了新型溶解微针贴片,并分别制备基于A/Puerto Rico/8/1934(H1N1)和A/duck/Hokkaido/Vac-3/2007(H5N1)的裂解病毒颗粒疫苗与全病毒颗粒疫苗,在小鼠中评估其效力。
主要发现
- 微针接种诱导的中和抗体应答高于皮下接种。
- 微针接种较低剂量抗原即可提供针对流感病毒致死攻击的保护性免疫,优于皮下接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transdermal vaccination using a microneedle (MN) confers enhanced immunity compared with subcutaneous (SC) vaccination. Here we developed a novel dissolving MN patch for the influenza vaccine. The potencies of split virion and whole virus particle (WVP) vaccines prepared from A/Puerto Rico/8/1934 (H1N1) and A/duck/Hokkaido/Vac-3/2007 (H5N1), respectively, were evaluated. MN vaccination induced higher neutralizing antibody responses than SC vaccination in mice. Moreover, MN vaccination with a lower dose of antigens conferred protective immunity against lethal challenges of influenza viruses than SC vaccination in mice. These results suggest that the WVP vaccines administered using MN are an effective combination for influenza vaccine to be further validated in humans.
引用
- Nakatsukasa A, Kuruma K, Okamatsu M, et al. Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice. Vaccine. 2017. PMID: 28431812. doi:10.1016/j.vaccine.2017.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。